Question 1

What is INCOBOTULINUMTOXINA used for?

Accepted Answer

INCOBOTULINUMTOXINA (brand name Xeomin) is a Other indicated for Excluding Spasticity Caused by Cerebral Palsy XEOMIN is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age, Horizontal Forehead Lines.

Question 2

How does INCOBOTULINUMTOXINA work?

Accepted Answer

INCOBOTULINUMTOXINA works through the following mechanism: 12.1 Mechanism of Action XEOMIN blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. In both muscles and glands, impulse transmission is re-established by the formation of new nerve endings..

Question 3

What are the most common side effects of INCOBOTULINUMTOXINA?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for INCOBOTULINUMTOXINA. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is INCOBOTULINUMTOXINA the same as Xeomin?

Accepted Answer

Xeomin is a brand name for INCOBOTULINUMTOXINA. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

INCOBOTULINUMTOXINA

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations